173 - Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study

Presenting Author(s)

• 

  David K. Hong, MD

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States

  Slides

Co-Author(s)

• SA

  Sibel Ascioglu, MD

  GSK, London, UK
  London, England, United Kingdom
• NB

  Nivedita Bhatt, PhD

  Spero Therapeutics
  Cambridge, Massachusetts, United States
• IC

  Ian A. Critchley, PhD

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States
• MG

  Masha Gaber, ALM

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States
• LG

  Leanne B. Gasink, MD

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States
• KH

  Kamal A. Hamed, MD

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States
• AH

  Aubri Hutchins, BA

  Spero Therapeutics Inc., Cambridge, MA, USA
  Cambridge, Massachusetts, United States
• AM

  Aoibhinn McDonnell, DVM

  GSK, Stevenage, UK
  Stevenage, England, United Kingdom
• TO

  Tal Otiker, MSc

  GSK, London, UK
  London, England, United Kingdom
• YS

  Yasmin Sánchez-Pearson, PhD

  GSK, London, UK
  London, England, United Kingdom
• AS

  Amanda J. Sheets, PhD

  GSK, Collegeville, PA, USA
  Collegeville, Pennsylvania, United States
• DS

  Dan Sotolongo, MD

  Links Clinical Trials, LLC, Miami, FL, USA
  Miami, Florida, United States
• MS

  Mike Sprys, MSc

  GSK, Philadelphia, PA, USA
  Philadelphia, Pennsylvania, United States
• DT

  Didem Torumkuney, PhD

  Scientific Director
  GSK
  Brentford, England, United Kingdom
• KW

  Kamil Wrzosek, MD

  Czerniakowski Hospital, Warsaw, Poland
  Warsaw, Mazowieckie, Poland
• AP

  Amanda Peppercorn, MD

  GlaxoSmithKline
  Cambridge, Massachusetts, United States